Breast Cancer Update, Issue 1, 2018


BCU118

Interview with Karen A Gelmon, MD

Track 1: MONARCH 2: Results of a Phase III trial of abemaciclib in combination with fulvestrant for women with ER-positive, HER2-negative advanced breast cancer (BC)
Track 2: Indirect comparison of the efficacy of abemaciclib, palbociclib and ribociclib
Track 3: Overall survival results from the Phase II PALOMA-1 (TRIO-18) trial of first-line letrozole with or without palbociclib in ER-positive, HER2-negative advanced BC
Track 4: TREnd: Results of a Phase II trial of palbociclib alone or in combination with the same endocrine therapy received prior to disease progression in ER-positive, HER2-negative metastatic BC (mBC)
Track 5: Case: A 64-year-old woman with ER/PR-positive, HER2-negative mBC achieves a good clinical response to palbociclib/letrozole on the PALOMA-2 trial
Track 6: Management of palbociclib-associated side effects
Track 7: Ongoing trials of CDK4/6 inhibitors in the (neo)adjuvant setting
Track 8: Selection of patients with ER-positive, HER2-negative mBC who can receive endocrine therapy alone in the front-line setting
Track 9: Everolimus and exemestane after disease progression on a CDK4/6 inhibitor
Track 10: Monitoring and management of everolimus-associated stomatitis and pneumonitis
Track 11: Activity and tolerability of immune checkpoint inhibitors for patients with mBC
Track 12: Case: A 42-year-old woman with multifocal, low ER-positive, HER2-positive, node-positive BC has residual invasive disease after neoadjuvant therapy
Track 13: CREATE-X: Results of a Phase III trial of adjuvant capecitabine for patients with HER2-negative residual invasive BC after neoadjuvant chemotherapy
Track 14: Caring for patients with ER-positive, HER2-positive, node-positive BC and residual disease after neoadjuvant therapy
Track 15: Efficacy and tolerability of neratinib as extended adjuvant therapy for patients with HER2-positive BC
Track 16: Results of APHINITY: A Phase III trial evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for patients with HER2-positive early BC
Track 17: Case: A 47-year-old premenopausal woman with a 2-cm, ER/PR-positive, HER2-negative, node-positive invasive lobular carcinoma of the breast and a 21-gene Recurrence Score® of 8
Track 18: Role of genomic assays for patients with ER-positive, node-positive BC
Track 19: Case: A 61-year-old woman with T1bN0 triple-negative BC (TNBC) and a BRCA mutation who underwent a prophylactic mastectomy and oophorectomy presents 9 months later with Stage III high-grade serous ovarian cancer
Track 20: Case: A 56-year-old woman with recurrent ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation receives olaparib after disease progression on multiple therapies
Track 21: Importance of BRCA mutation testing in patients with BC
Track 22: Activity of PARP inhibitors in patients with BRCA mutation-positive mBC
Track 23: OlympiAD: Results of a Phase III trial of olaparib monotherapy versus chemotherapy for patients with HER2-negative mBC and a germline BRCA mutation
Track 24: Approach to patients with mTNBC harboring germline BRCA mutations; BRCA testing in patients with other solid tumors

Interview with Lisa A Carey, MD

Track 1: Case: A 37-year-old woman with Stage II ER-negative, HER2-positive BC achieves a good response to neoadjuvant trastuzumab/pertuzumab and chemotherapy
Track 2: Efficacy of neoadjuvant HER2-targeted therapy for patients with HER2-positive BC
Track 3: Perspective on using adjuvant pertuzumab or extended adjuvant neratinib for patients with HER2-positive BC and residual disease after neoadjuvant therapy
Track 4: Management of neratinib-associated side effects
Track 5: Case: A 66-year-old woman with Stage II ER-negative, HER2-positive BC achieves a pathologic complete response to neoadjuvant trastuzumab/pertuzumab on the TBCRC 026 trial
Track 6: Management of the axilla in patients with node-positive BC
Track 7: APT trial: Results after a 7-year follow-up of adjuvant paclitaxel/trastuzumab for node-negative, HER2-positive BC
Track 8: Selection of adjuvant therapy in younger versus older patients with HER2-positive, node-positive BC
Track 9: Case: A 54-year-old woman with Stage II, ER-positive invasive lobular cancer of the right breast
Track 10: Genomic assays to predict the risk of distant recurrence and benefit of extended endocrine therapy in patients with ER-positive BC
Track 11: Use of genomic assays to guide adjuvant decision-making for patients with node-positive, ER-positive BC
Track 12: Case: A 55-year-old woman with mTNBC achieves a partial response on the SWOG-S1416 trial of cisplatin with or without veliparib
Track 13: Therapeutic options for patients with mTNBC after disease progression on first-line chemotherapy
Track 14: Clinical experience with immune checkpoint inhibitors for patients with mTNBC
Track 15: De-escalating and escalating systemic therapy in TNBC
Track 16: Integration of CDK4/6 inhibitors into the treatment algorithm for patients with ER-positive, HER2-negative mBC
Track 17: Clinical implications of the Phase III OlympiAD trial of olaparib monotherapy for patients with germline BRCA-mutant, HER2-negative mBC
Track 18: Choice of second-line therapy for patients with ER-positive, HER2-negative mBC and germline BRCA mutations
Track 19: Efficacy and tolerability of PARP inhibitors
Track 20: Unmet needs in clinical research in BC
Track 21: Clinical significance of ESR1 mutations for patients with ER-positive BC
Track 22: Areas for investigation in BC research with the greatest potential for clinical and therapeutic application
 
FACULTY
 
Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research
Chief, Division of Hematology and Oncology
Physician-in-Chief
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
 
Karen A Gelmon, MD
Professor, Medicine
Head, Division of Medical Oncology
University of British Columbia
Medical Oncologist, BC Cancer Agency
Vancouver Cancer Centre
Vancouver, Canada
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida